Cargando…

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin

Two phase I trials of irinotecan (CPT‐11) in combination with cisplatin were conducted. In both cases, the dose‐limiting toxicities were leukopenia and/or diarrhea. During these trials the pharmacokinetics of CPT‐11 and its active metabolite, 7‐ethyl‐10‐hydroxycamptothecin (SN‐38), were investigated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudoh, Shinzoh, Fukuoka, Masahiro, Masuda, Noriyuki, Yoshikawa, Atsuko, Kusunoki, Yoko, Matsui, Kaoru, Negoro, Shun‐ichi, Takifuji, Nobuhide, Nakagawa, Kazuhiko, Hirashima, Tomonori, Yana, Takashi, Takada, Minoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1995
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920836/ https://www.ncbi.nlm.nih.gov/pubmed/7775263 http://dx.doi.org/10.1111/j.1349-7006.1995.tb03071.x

Ejemplares similares

Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts
por: Kudoh, Shinzoh, et al.
Publicado: (1993)

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
por: Masuda, N., et al.
Publicado: (1993)

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy
por: Matsui, Kaoru, et al.
Publicado: (1996)

Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer
por: Masuda, Noriyuki, et al.
Publicado: (2010)

Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts
por: Tamura, Kenji, et al.
Publicado: (1997)

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
por: Negoro, S, et al.
Publicado: (2003)

Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer
por: Takeda, K, et al.
Publicado: (1999)

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
por: Fukuoka, M., et al.
Publicado: (1997)

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
por: Matsui, K., et al.
Publicado: (1998)

Photodynamic Therapy With YAG-OPO Laser for Early Stage Lung Cancer
por: Kato, Harubumi, et al.
Publicado: (1997)

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)
por: Yamamoto, N, et al.
Publicado: (2004)

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
por: Yamada, M, et al.
Publicado: (2002)

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
por: Matsui, K., et al.
Publicado: (1996)

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B(12) in Japanese patients with solid tumours
por: Nakagawa, K, et al.
Publicado: (2006)

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer
por: Okunaka, Mashiro, et al.
Publicado: (2021)

Herbal Medicines for Irinotecan-Induced Diarrhea
por: Tang, Liu, et al.
Publicado: (2019)

Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay.
por: Takada, M., et al.
Publicado: (1995)

Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
por: Kimura, Tatsuo, et al.
Publicado: (2011)

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
por: Tamura, K, et al.
Publicado: (2008)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

A case of primary small cell carcinoma of the liver that was treated with chemotherapy
por: Morikawa, Hiroyasu, et al.
Publicado: (2008)

Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
por: Takada, M., et al.
Publicado: (1996)

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
por: Sekine, I, et al.
Publicado: (2008)

Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue.
por: Masuda, N., et al.
Publicado: (1998)

A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
por: Takashima, Tsutomu, et al.
Publicado: (2016)

Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group
por: Murakami, Haruyasu, et al.
Publicado: (2014)

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
por: Masuda, N., et al.
Publicado: (1998)

A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
por: Yashiro, M, et al.
Publicado: (2013)

Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats
por: Deng, Chao, et al.
Publicado: (2017)

Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer
por: Lu, Hongyang, et al.
Publicado: (2018)

Clinical Study on Prevention of Irinotecan-Induced Delayed-Onset Diarrhea by Hot Ironing with Moxa Salt Packet on Tianshu and Shangjuxu
por: Lai, Xianghong, et al.
Publicado: (2022)

Vitamin A Ameliorated Irinotecan-Induced Diarrhea in a Piglet Model Involving Enteric Glia Modulation and Immune Cells Infiltration
por: Li, Meng, et al.
Publicado: (2022)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
por: Yue, Bei, et al.
Publicado: (2021)

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
por: Mahdy, Marwa S., et al.
Publicado: (2023)

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer
por: Tsuda, H, et al.
Publicado: (2004)

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
por: Ryuge, Shinichiro, et al.
Publicado: (2009)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

Direct Induction of Chondrogenic Cells from Human Dermal Fibroblast Culture by Defined Factors
por: Outani, Hidetatsu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rbvm08k58qmvf8kn574puorhag